Resveratrol effect on patients with non-alcoholic fatty liver disease: A matter of dose and treatment length

Diabetes Obes Metab. 2018 Jul;20(7):1798-1799. doi: 10.1111/dom.13324. Epub 2018 May 2.

Authors

Federica Fogacci¹, Maciej Banach², Arrigo Francesco Giuseppe Cicero¹

Affiliations

¹ Hypertension and Atherosclerosis Research Unit, Medical and Surgical Sciences Department, Sant'Orsola-Malpighi University Hospital, Bologna, Italy.
² Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland.

PMID: 29656521
DOI: 10.1111/dom.13324

No abstract available

Publication types

Letter
Comment

MeSH terms

Dietary Supplements
Double-Blind Method
Humans
Insulin
Non-alcoholic Fatty Liver Disease*
Overweight
Resveratrol

Substances

Insulin
Resveratrol